Introduction
The airway epithelium, as well as acting as a barrier between the outside and inside environment, also appears to have important metabolic and immunological properties. In this context, bronchial epithelial cells can actively release a range of mediators which participate in inflammatory and healing processes and which modulate immune responses within the lung. The development of any inflammatory response depends upon efficient antigen presentation to relevant leukocytes, the mobilization of these cells to the inflammatory site, and their attachment to the target cells, all of these steps being dependent on cell-to-cell contact. A basic mechanism for cellular interaction involves the expression of class II human leukocyte antigens (HLA), such as HLA-DR. These major histocompatibility (MCH) class II gene products have a functional role in guiding helper T-cells in the recognition of extrinsic antigens and in the subsequent initiation of an immune response. HLA-DR molecules are expressed constitutively by B cells, activated T-cells, dendritic cells, macrophages and, at lower levels, by other cell types, such as endothelial and some epithelial cells, and their expression can be induced or increased by inflammatory stimuli, including cytokines. A further mechanism allowing close cell-to-cell contact is dependent upon the expression of cell adhesion proteins, such as the intercellular adhesion molecule-1 (ICAM-1 or CD54), which belongs to the immunoglobulin superfamily. ICAM-1 is constitutively expressed by only a few cell types, 5, 8 but its expression can be specifically upregulated by inflammatory mediators such as interferon-, (IFN-T), interleukin-1 (IL-1), and tumour necrosis factor-or (IFN-00. 5 (Fig. 1A and 1B) . Similarly, the addition of different concentrations of BMC-CM (0.5, 1 and 3%) to BEC induced, after 36 h, a dose-dependent increase of HLA-DR ( Fig. 1) and ICAM-1 expression (Fig. 2) , while the supernatant from the control (unstimulated BMCs) had no effect on the cell surface antigen expression. The relative fluorescence intensity related to the intensity of HLA-DR molecule expression showed a similarly close correlation with the concentration of IFN-,(p < 0.01) and of the PHAstimulated BMC-CM (p < 0.01) (Fig. 1 (Fig.  3 ) at all the concentrations tested, and the effect was (Fig. 4 ). In contrast with the effect which had been observed on HLA-DR expression, dexamethasone had a significantly stronger effect when compared with nedocromil (p < 0.05) at all the concentrations which had proved to be effective (from 10 -4 to 10 -7 M). The two drugs together showed a significant synergistic effect at doses ranging from 10 -to 10 -9 M, and this was also observed at concentrations (10 -8 to 10 -9 M) which had proved ineffective when both drugs were used alone (Fig. 4) .
Discussion
In this study, using BEC primary cultures, we have demonstrated that: (a) the expression of HLA-DR and ICAM-1 molecules, on BEC can be upregulated by supernatants from BMC-CM as well as by IFN-y; (b) nedocromil sodium shows a dose-dependent inhibitory effect on the expression of these activation surface molecules, this effect being stronger on HLA-DR than on ICAM-1 expression; (c) a similar dosedependent inhibitory effect is observed using dexamethasone, which appears to be less active than nedocromil on HLA-DR expression and more active on ICAM-1 expression. HLA-DR molecules are expressed on the surface of a wide variety of cells belonging to the immune system, such as B lymphocytes, dendritic cells, monocytes, macrophages and activated T lymphocytes. 
